Loading
CT
Cidara Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by RA CAPITAL MANAGEMENT, L.P., was filed 30 Jun 2025.
Cidara Therapeutics, Inc.: what insiders have been doing
Cidara Therapeutics, Inc., classified in the Healthcare & Pharma sector, is a listed company based in San Diego, United States, founded in 2013. Its insiders report their share dealings to SEC (Form 4). Between 22 October 2025 and 22 October 2026, 8 insiders published 35 filings.
All open-market trades in the period are sales: 1 sale worth €1.9M, by 1 insider, with no purchase on record. Ward Shane filed the largest sale, €1.9M, on 12 December 2025.
With 35 filings in twelve months, the company is more active than the median of 24 filings across the 3,171 companies we follow on the same exchange. Our records for Cidara Therapeutics, Inc. go back to 2016, with 26 purchases and 42 sales on the open market in total.
The median gap between a trade and its publication by SEC (Form 4) is 7 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
173
Thresholds
n/a
Buy Volume
€88M
26 ops. · all time
Sell Volume
€2M
42 ops. · all time
Who traded when
BuySaleChrysa Mineo2 buys
Shane Ward2 sales
Leslie Tari1 sale
Nicole Negar Davarpanah1 sale
RA Capital Management, L.P.1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$3.7M
Net income-US$146.2M-3917.6% margin
Last declaration on 9 January 2026
Declarations173 total
4,652,309 shares@ US$221.5090.6% of flowCommon StockSEC:0001231919-26-000031:1
1,286,786 shares0.0% of flowCommon StockSEC:0001231919-26-000031:0
8,333 sharesCommon StockSEC:0002067554-26-000002:1
43,125 sharesCommon StockSEC:0001276700-26-000002:1
750 shares@ US$118.95Common StockSEC:0001478831-26-000004:3
367 shares@ US$135.80Common StockSEC:0001478831-26-000004:5
2,500 shares@ US$40.01Common StockSEC:0001478831-26-000004:7
658 shares0Common StockSEC:0001478831-26-000004:9
1,873 shares0Common StockSEC:0001478831-26-000004:10
937 shares0Common StockSEC:0001478831-26-000004:11
2,379 shares@ US$221.502.7% of flowCommon StockSEC:0001478831-26-000005:1
67,498 shares@ US$221.5077.0% of flowCommon StockSEC:0001478831-26-000005:2
270 sharesCommon StockSEC:0001478831-26-000004:0
12,553 shares@ US$221.5054.6% of flowCommon StockSEC:0002067554-26-000002:0
25,083 shares@ US$221.5062.2% of flowCommon StockSEC:0001638380-26-000002:0
3,320 shares@ US$221.5093.6% of flowCommon StockSEC:0001575644-26-000002:0
5,763 shares@ US$221.5058.2% of flowCommon StockSEC:0001478831-26-000005:0
7,526 shares@ US$221.5050.9% of flowCommon StockSEC:0001276700-26-000002:0
150 shares@ US$221.50100.0% of flowCommon StockSEC:0001239650-26-000002:0
15 shares@ US$221.50100.0% of flowCommon StockSEC:0001683607-26-000006:0
10,638 shares0Common StockSEC:0001478831-25-000004:5
5,425 shares0Common StockSEC:0001478831-25-000004:6
33,072 shares0Common StockSEC:0001478831-25-000004:1
2,244 shares0Common StockSEC:0001478831-25-000004:2
2,244 shares0Common StockSEC:0001478831-25-000004:3
25 of 173 declarations
About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. is a U.S.-based biotechnology company listed on the NASDAQ Global Market under the ticker CDTX in the United States. The company is headquartered in San Diego, California. Founded in 2012, it was originally incorporated in Delaware as K2 Therapeutics, Inc. and later changed its name to Cidara Therapeutics, Inc. in 2014. Cidara’s strategy is centered on its proprietary Cloudbreak® platform, which is designed to create drug-Fc conjugate (DFC) therapeutics aimed at serious diseases, with a particular emphasis on infectious disease and antiviral prevention. ([cidara.com](https://www.cidara.com/investors/info/?utm_source=openai))
From a business perspective, Cidara has historically worked on several product candidates, but its most advanced program is CD388, a highly potent antiviral being developed as a universal preventive therapy for seasonal and pandemic influenza. CD388 has progressed through multiple clinical stages, including two Phase 1 studies and an earlier Phase 2a study, and in 2025 the company initiated the global Phase 3 ANCHOR trial. This makes CD388 the central value driver in the investment case and the main source of long-term upside, while also highlighting the binary nature of biotech development risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1610618/000161061825000096/cdtx-20250930.htm?utm_source=openai))
Read moreShow less
Cidara’s competitive position is that of a specialized, innovation-driven biotech rather than a diversified commercial pharmaceutical company. Its differentiation lies in the Cloudbreak platform and in its focus on infectious diseases, where prevention and treatment options remain limited relative to the scale of unmet need. The company previously marketed REZZAYO® (rezafungin) in the United States for candidemia and invasive candidiasis, but in 2024 it sold its rezafungin assets and related contracts to Napp, an affiliate of Mundipharma, effectively narrowing its portfolio and concentrating resources on CD388. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1610618/000161061825000096/cdtx-20250930.htm?utm_source=openai))
Recent company-specific developments have been material. In September 2025, Cidara entered into a BARDA agreement to support expanded manufacturing and clinical development of CD388, including U.S. onshoring of manufacturing and additional clinical work, with potential total BARDA investment of up to $339.2 million. That same period, the company’s profile gained further strategic visibility when Merck announced a definitive agreement to acquire Cidara for $221.50 per share in cash, implying a transaction value of approximately $9.2 billion. For investors, Cidara combines platform science, late-stage clinical execution and major M&A optionality, but it remains a high-risk biotech dependent on regulatory, clinical and integration outcomes. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001610618/000161061825000089/cdtx-20250930.htm?utm_source=openai))
